Foreign establishment requirements
This article was originally published in The Gray Sheet
Executive Summary
Firms in countries with which the U.S. has free trade agreements should not be required to identify U.S. agents, the Medical Device Manufacturers Association asserts in Oct. 7 comments on FDA's May 14 proposed rule to implement foreign establishment provisions in Sec. 417 of FDAMA. MDMA acknowledges the need for foreign companies to register and list their products with FDA, but maintains that these requirements "should be sufficient to protect patient safety and the public health." The comments follow earlier MDMA complaints that FDA's April 2 proposed rule concerning device companies exporting products was too stringent in its notification and recordkeeping requirements (1"The Gray Sheet" May 31, p. 9)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.